Citi Boosts Eli Lilly with Buy Rating, Eyes Growth
Citi resumes Eli Lilly coverage with Buy rating, driven by optimistic tirzepatide forecasts for diabetes and obesity treatments.
- Latest
- Trending
Citi resumes Eli Lilly coverage with Buy rating, driven by optimistic tirzepatide forecasts for diabetes and obesity treatments.
Explore how VR exergaming leverages AI and sensors to enhance physical fitness through personalized, engaging experiences.
Google, Microsoft to offer free cyber defenses for small hospitals to combat increasing data breaches.
A purring cat can alleviate stress, offering a glimpse of a world with optimal stress management, fostering harmony and reducing ...
The Apple Watch Series 9 is now at its lowest price yet, with a 25% discount. It offers faster on-device ...
The INIU 10000mAh Portable Charger is the best and most affordable option on the market. With deals on Adidas and ...
Apple has won a legal victory as a judge dismissed an antitrust lawsuit related to heart rate apps on the ...
Discover how sleep technology has evolved to include smart mattresses, wearable sleep trackers, and light therapy devices for better sleep. ...
Garmin starts off the year with a simplified and customizable experience in its redesigned Connect app, bridging the gap between ...
In a battle for the wrists, Fitbit and Apple Watch compete in the wearable health and fitness market. Let's analyze ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.